Chiasma Inc. (NASDAQ:CHMA) shares fell 5.4% on Monday . The company traded as low as $2.81 and last traded at $2.82, with a volume of 70,063 shares trading hands. The stock had previously closed at $2.98.

A number of research firms recently weighed in on CHMA. Zacks Investment Research cut shares of Chiasma from a “hold” rating to a “sell” rating in a research note on Tuesday, April 12th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $43.00 target price on shares of Chiasma in a research note on Tuesday, March 15th. Cowen and Company restated an “outperform” rating and set a $32.00 target price (down previously from $43.00) on shares of Chiasma in a research note on Tuesday, March 15th. William Blair cut shares of Chiasma from an “outperform” rating to a “market perform” rating in a research note on Monday, April 18th. Finally, Barclays PLC restated a “buy” rating and set a $40.00 target price on shares of Chiasma in a research note on Thursday, March 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $19.70.

The stock’s 50 day moving average price is $2.94 and its 200 day moving average price is $7.69. The company’s market cap is $68.53 million.

Chiasma (NASDAQ:CHMA) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.08. Analysts predict that Chiasma Inc. will post ($2.81) earnings per share for the current year.

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.